跳至主要内容
临床试验/NCT05569096
NCT05569096尚未招募不适用

Clinical Significance of Circulating T Regulatory Cells , Soluble CD25 and CXCL9 to Assess Disease Activity of Vitiligo.

Assiut University0 个研究点目标入组 40 人开始时间: 2024年1月最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
40
主要终点
To assess role of circulating T regulatory cells, soluble CD25 and CXCL9 in disease activity of vitiligo

研究概览

简要总结

Clinical significance of circulating T regulatory cells , soluble CD25 and CXCL9 to assess disease activity of vitiligo.

详细描述

Vitiligo is an acquired and polygenic skin depigmenting disease characterized by bilateral, symmetrical depigmented patches over the entire body.

Its pathogenesis is multifactorial; however, the exact mechanisms that integrate the individual genetic susceptibility, melanocyte auto aggression, and failure of immune tolerance mechanisms are still not fully understood. The presence of these autoreactive CD8+ and CD4+ T cells in vitiligo patients' skin and blood samples . indicates a dysregulation of regulatory T-cell mechanism, which can suppress these cells.

Previous studies have reported an altered Treg cell frequency and function in vitiligo patients.

FoxP3 is the key transcriptional regulators of Tregs which mediate Treg cell function by repressing the expression of cytokines (IL2 and IL4 ) and upregulate the Treg cell markers (CTLA-4 and CD25 ).

Expression of IL-2 and its receptor CD25 are the most fundamental events in the host immune response. Thus any disorder in which T lymphocyte activation occurs at a substantial level is expected to induce expression of CD25 beyond ambient levels; this had been reported in atopic asthma, multiple sclerosis, allergic responses.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Retrospective

入排标准

年龄范围
15 Years 至 65 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The patients will be enrolled in the study if they have :-
  • Non segmental vitiligo.

排除标准

  • The following patients were excluded from this study:
  • Patients receiving systemic treatment in the last two months.
  • Patients with any autoimmune disease, such as rheumatoid arthritis. inflammatory bowel disease, psoriasis, or systemic lupus erythematosus; patients with type 1 diabetes mellitus.
  • Patients with any thyroid and/or neoplastic diseases.

结局指标

主要结局

To assess role of circulating T regulatory cells, soluble CD25 and CXCL9 in disease activity of vitiligo

时间窗: Baseline

compare presences of T regulatory cells , soluble CD25 and CXCL9 between healthy control and vitiligo patients. To assess role of circulating T regulatory cells, soluble CD25 and CXCL9 in disease activity of vitiligo

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jian Hashim Mohammed , MD

Assistant Lecturer

Assiut University

相似试验